Anthony Hamlett

1.7k citations

20 papers · 1.2k indexed · 1 hit paper · h-index 9

Impact in

Pathology and Forensic Medicine top 1%
- Multiple Sclerosis Research Studies
Neurology top 5%
- Peripheral Neuropathies and Disorders

Papers in

Pathology and Forensic Medicine 11
- Multiple Sclerosis Research Studies 8
Genetics 6
- Chronic Lymphocytic Leukemia Research 6

Co-authors: Per Soelberg Sørensen Peter Rieckmann Gavin Giovannoni Patrick Vermersch Kottil Rammohan Stuart D. Cook Steven J. Greenberg Bruno Musch
Journals: Journal of Clinical Oncology (3 papers)Journal of the Neurological Sciences (2 papers)Neurology (2 papers)Blood (2 papers)Multiple Sclerosis and Related Disorders (1 paper)
Partner nations: United States United Kingdom Switzerland

In The Last Decade

Anthony Hamlett

20 papers receiving 1.2k citations

Hit Papers

align trajectories log scale

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis 2010 · 689 citations

Peers

Countries citing papers authored by Anthony Hamlett

Since Specialization

Citations

This map shows the geographic impact of Anthony Hamlett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony Hamlett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony Hamlett more than expected).

Fields of papers citing papers by Anthony Hamlett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony Hamlett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony Hamlett. The network helps show where Anthony Hamlett may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Anthony Hamlett, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anthony Hamlett Line = papers co-authored together Anthony Hamlett links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma Blood ·Connie Lee Batlevi, Steven I. Park, Loretta J. Nastoupil, Tycel Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pam McKay, John M. Pagel, John P. Leonard, Jay Yang, Eligio Salamanca, Anthony Hamlett, Deyaa Adib, Franck Morschhauser	2021	5
2	Results of the phase 1b soft-tissue sarcoma (STS) portion of the global randomized, double-blind, placebo-controlled study of tazemetostat (TAZ) plus doxorubicin (DOX) as frontline therapy for advanced epithelioid sarcoma (ES). Journal of Clinical Oncology ·Sant P. Chawla, Gerald S. Falchook, Melissa Burgess, PS Batista, Robin L. Jones, Katherine Cannon, Coya Tapia, Hyeongmo Kim, Anthony Hamlett, Melinda S. Merchant, Rashmi Chugh	2021	3
3	A phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma. Journal of Clinical Oncology ·Shiraj Sen, Meredith McKean, Laura Sierra, Hyeongmo Kim, Jay Yang, Anthony Hamlett, Leili Segura Quiñonez, Melinda S. Merchant, Sant P. Chawla	2020	5
4	A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology ·Wassim Abida, Thomas Bradley, Arash Rezazadeh, Lawrence I. Karsh, Ashley E. Ross, Daniel R. Saltzstein, Shicheng Zou, Anthony Hamlett, Wu Chengjia, Deyaa Adib	2020	1
5	Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Blood ·Meletios Α. Dimopoulos, Sara Bringhen, Pekka Anttila, Marcelo Capra, Michèle Cavo, Craig E. Cole, Cristina Gasparetto, Tobey Crockett, Matthew Jenner, Vladimir Vorobyev, Eduardo Yañez Ruiz, Jianyun Yin, Anthony Hamlett, Ravi Vij	2018	16
6	Oral Cladribine as Add on to IFN β Therapy in Patients with Active Multiple Sclerosis: Results from the Phase II ONWARD Study (P07.099) Neurology ·Xavier Montalbán, Bruce A. Cohen, Thomas Leist, Harold Moses, Anthony Hamlett, Matthew Scaramozza, Nathalie Lachenal	2013	2
7	Safety and Efficacy of Oral Cladribine in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the 96 Week Phase IIIb Extension Trial to the CLARITY Study (P07.119) Neurology ·Gavin Giovannoni, Gıancarlo Comı, Stuart D. Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Anthony Hamlett, Matthew Scaramozza, Nathalie Lachenal	2013	5
8	MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study Journal of Neurology ·Gıancarlo Comı, Stuart D. Cook, Gavin Giovannoni, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Anthony Hamlett, Vissia Viglietta, Steven J. Greenberg	2012	49
9	Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis The Lancet Neurology ·Gavin Giovannoni, Stuart D. Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Anthony Hamlett, Vissia Viglietta, Steven J. Greenberg	2011	180
10	Cladribine tablets for relapsing–remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study Multiple Sclerosis and Related Disorders ·Kottil Rammohan, Gavin Giovannoni, Cristoforo Comi, Stuart D. Cook, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Anthony Hamlett, Nuwan Kurukulasuriya	2011	29
11	Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study Multiple Sclerosis Journal ·S. D. Cook, Patrick Vermersch, Cristoforo Comi, Gavin Giovannoni, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Anthony Hamlett, Montserrat Miret, Joseph Weiner, Vissia Viglietta, Bruno Musch, SJ Greenberg	2011	102
12	A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis New England Journal of Medicine ·Gavin Giovannoni, Gıancarlo Comı, Stuart D. Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch, Steven J. Greenberg Hit paper breakdown →	2010	689
13	Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled CLARITY study UCL Discovery (University College London) ·Peter Rieckmann, G. Comi, Sandra Cook, Gavin Giovannoni, Judith Marin, Per Soelberg Sørensen, Patrick Vermersch, Pen-Heng Chang, Anthony Hamlett, Joyce Richard, Bruno Musch, Stan S. Greenberg	2009	9
14	Results from the CLARITY Study: a Phase III, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Oral Cladribine in Relapsing-Remitting Multiple Sclerosis (RRMS) Gavin Giovannoni, Giacomo P. Comi, Elaine P. McCammon, Judith Marin, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Paul Chang, Anthony Hamlett, Bruno Musch, SJ Greenberg	2009	6
15	PO10-TU-39 Safety and tolerability of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study Journal of the Neurological Sciences ·電機連合, P. Vermersch, Giacomo P. Comi, Gavin Giovannoni, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Pei‐Hung Chang, Anthony Hamlett, Bruno Musch, Vissia Viglietta, SJ Greenberg	2009	5
16	MRI outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study Giacomo P. Comi, Sandra Cook, Gavin Giovannoni, Judith Marin, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Paul Chang, Anthony Hamlett, Bruno Musch, Andrew Slessor, Joyce Richard, Stan S. Greenberg	2009	1
17	FP36-WE-03 MRI outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study Journal of the Neurological Sciences ·G. Comi, 電機連合, Gavin Giovannoni, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, P. Vermersch, Pei‐Hung Chang, Anthony Hamlett, Bruno Musch, Andrew Slessor, Vissia Viglietta, SJ Greenberg	2009	1
18	Issues and trends in pediatric growth hormone therapy--an update from the GHMonitor observational registry. PubMed ·Pisit Pitukcheewanont, Paul Desrosiers, Joel Steelman, Robert Rapaport, John S. Fuqua, Lindén Joel, Anthony Hamlett	2008	10
19	Mixed Models for Assessing Correlation in the Presence of Replication Journal of the Air & Waste Management Association ·Anthony Hamlett, Louise Ryan, О А Мамаев, Russ Wolfinger	2003	80
20	Dose Spacing in Early Dose Response Clinical Trial Designs Drug Information Journal ·Anthony Hamlett, Naitee Ting, R. Choudary Hanumara, Wen-Ting Peng	2002	8

About Anthony Hamlett

Anthony Hamlett is a scholar working on Pathology and Forensic Medicine, Genetics, Hematology, Statistics and Probability and Oncology, having authored 20 papers that have together received 1.2k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (8 papers), Chronic Lymphocytic Leukemia Research (6 papers), Polyomavirus and related diseases (3 papers), Acute Lymphoblastic Leukemia research (3 papers), Cancer-related gene regulation (3 papers), Peripheral Neuropathies and Disorders (2 papers), Multiple Myeloma Research and Treatments (2 papers) and Protein Degradation and Inhibitors (2 papers). The work is most often cited by research in Pathology and Forensic Medicine (953 citations), Neurology (308 citations), Genetics (183 citations), Oncology (411 citations) and Rheumatology (215 citations). Anthony Hamlett has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include Per Soelberg Sørensen, Peter Rieckmann, Gavin Giovannoni, Patrick Vermersch, Kottil Rammohan, Stuart D. Cook, Steven J. Greenberg, Bruno Musch, Gıancarlo Comı and Peter Chang. Their work appears in journals such as Journal of Clinical Oncology, Journal of the Neurological Sciences, Neurology, Blood and Multiple Sclerosis and Related Disorders.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact